Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 2/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HRH2 | P25021 | 2/20 | 0.32 |
| ▸ | HRH1 | P35367 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22890951 | 0.88 | KDM1A (0.38) | GNAI3GNAO1GNAI1SIGMAR1HRH3 | |
| SCHEMBL21377181 | 0.87 | HRH3 (0.40) | GNAI3GNAO1GNAI1SIGMAR1HRH3 | |
| SCHEMBL22890929 | 0.85 | HRH3 (0.41) | SIGMAR1HRH3MAOBMEN1KMT2A | |
| SCHEMBL25467828 | 0.83 | GNAI3 (0.40) | GNAI3GNAO1GNAI1HRH3 | |
| SCHEMBL13543410 | 0.82 | MEN1 (0.46) | HRH3MAOBMEN1KMT2A | |
| SCHEMBL25467854 | 0.81 | GNAI3 (0.42) | GNAI3GNAO1GNAI1HRH3 | |
| SCHEMBL25467853 | 0.81 | GNAI3 (0.42) | GNAI3GNAO1GNAI1HRH3 | |
| SCHEMBL13543156 | 0.81 | MEN1 (0.45) | HRH3MAOBMEN1KMT2AHRH1 | |
| SCHEMBL2603221 | 0.81 | HTR4 (0.37) | GNAI3GNAO1GNAI1SIGMAR1HRH3 | |
| SCHEMBL22663366 | 0.81 | HRH3 (0.40) | GNAI3GNAO1GNAI1HRH3HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11230557-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20210008041-A1 | MTORC MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210008041-A1 | MTORC MODULATORS AND USES THEREOF | MTOR, RICTOR, RPTOR | GNAI3 1064/4885GNAO1 2536/4885GNAI1 1082/4885 |
| US-11230557-B2 | mTORC modulators and uses thereof | MTOR, RICTOR, RPTOR | GNAI3 1064/4885GNAO1 2536/4885GNAI1 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.